One To Watch

Neurocrine Biosciences

A San Diego-based biopharmaceutical company that has built a $2.83 billion commercial franchise around neurological and endocrine disorders, anchored by INGREZZA in tardive dyskinesia and the first new CAH treatment in roughly seven decades.

Company Overview

Neurocrine Biosciences has built a $2.83 billion commercial franchise around neurological and endocrine disorders, anchored by INGREZZA in tardive dyskinesia and the first new CAH treatment in roughly seven decades. Founded in 1992 and headquartered in San Diego, California, the company focuses on neurological, endocrine, and psychiatric disorders where target biology is well-understood but treatment options remain poor. Two approved products now generate the revenue base that funds a mid-to-late-stage pipeline spanning depression, epilepsy, and schizophrenia. The December 2024 approval of Crenessity marks the opening of a second commercial franchise — and a direct challenge to seven decades of glucocorticoid-only CAH management.

Headquarters and Global Presence

Neurocrine is headquartered in San Diego, California, with commercial and clinical operations primarily in the United States. Its acquisition of UK-based Diurnal extended its reach into European endocrinology, complementing the US launch of Crenessity.

Founding and History

Neurocrine was founded in 1992 with a focus on stress hormones and the corticotropin-releasing factor pathway — science that eventually yielded Crenessity three decades later. The transformative commercial milestone came on April 11, 2017, when INGREZZA became the first FDA-approved treatment for tardive dyskinesia, converting Neurocrine into a profitable, revenue-generating company. Patent litigation over generic INGREZZA was resolved in November 2023, with settlement terms providing exclusivity runway through at least March 2038. Kyle W. Gano, Ph.D., succeeded longtime CEO Kevin Gorman effective October 11, 2024, opening a new leadership chapter as the company diversifies beyond its INGREZZA foundation.

Therapy Areas and Focus

Neurocrine sits at the intersection of neurology, psychiatry, and endocrinology — three areas where chronic undertreatment and poor tolerability of existing options define the commercial opportunity. Tardive dyskinesia, a movement disorder caused by prolonged antipsychotic use, remains the revenue engine. Classic congenital adrenal hyperplasia represents a rare endocrine condition where patients have been managed for decades solely with supraphysiologic glucocorticoid doses that carry serious metabolic consequences. The emerging pipeline targets major depressive disorder and epilepsy, extending the CNS franchise beyond movement disorders.

Technology Platforms and Modalities

INGREZZA (valbenazine) works as a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, reducing dopamine release at the synapse to suppress involuntary movements in tardive dyskinesia and Huntington's-associated chorea. Head-to-head data have demonstrated higher VMAT2 target occupancy for INGREZZA versus AUSTEDO XR, a commercially relevant differentiation point in a contested market. Crenessity (crinecerfont) operates through an entirely different mechanism — antagonism of the corticotropin-releasing factor type 1 (CRF1) receptor — suppressing ACTH-driven androgen excess at the pituitary level rather than blunting it downstream with steroids. Osavampator (NBI-1065845), the lead CNS pipeline asset, works through a distinct mechanism being evaluated in depression and schizophrenia.

Key Pipeline and Programs

Crenessity (crinecerfont) is a first-in-class oral CRF1 receptor antagonist approved by the FDA on December 13, 2024, for adults and pediatric patients four years and older with classic CAH. The approval was supported by Phase III CAHtalyst trials enrolling 182 adults and 103 children. Two-year open-label extension data from the CAHtalyst Pediatric study — presented at ENDO 2026 and the Pediatric Endocrine Society 2026 Annual Meeting — showed mean glucocorticoid doses falling from 16.4 to 13.2 mg/m²/day, 60% of patients with obesity at baseline achieving clinically meaningful BMI improvements, and slowed bone age progression with improved predicted adult height in those with advanced baseline bone age.

Osavampator (NBI-1065845) is the company's lead CNS pipeline candidate, currently in Phase III evaluation for major depressive disorder. Top-line data are expected in late 2026, representing the most immediate binary catalyst for the stock and pipeline narrative. The program also has reach into schizophrenia, broadening the potential label if the depression data are supportive.

NBI-921355 is an anti-epileptic candidate in Phase II development, while NBI-1065890 is being evaluated in a Phase II study in tardive dyskinesia — a program that both deepens the movement-disorder franchise and hedges against the eventual generic INGREZZA entry in 2038.

Recent Developments

Crenessity launched commercially in the US on December 20, 2024, and generated $301.2 million in net product sales in 2025 — a strong first full year that demonstrates real patient demand in a disease long starved of new options. Two-year durability data presented at ENDO 2026 strengthen the pediatric label narrative, particularly on growth and metabolic outcomes that matter most to prescribers treating children. Sanjay Keswani, M.D., joined as chief medical officer effective June 2, 2025, replacing Eiry Roberts and signaling a pipeline-execution focus as the late-stage readouts approach. Full-year 2025 net product sales reached $2.83 billion, up 22% year over year, with INGREZZA contributing $2.51 billion.

Key Personnel

Kyle W. Gano, Ph.D., serves as chief executive officer, having taken the role effective October 11, 2024, succeeding Kevin Gorman who had led the company through its INGREZZA-era growth. Sanjay Keswani, M.D., serves as chief medical officer effective June 2, 2025, leading clinical development and medical affairs as the company approaches pivotal late-stage readouts. David-Alexandre Gros joined as president and chief operating officer, adding operational depth to a leadership team navigating Neurocrine's transition to a two-product commercial company.

Strategic Partnerships

Neurocrine licensed the global rights to Idorsia's ACT-709478, a pediatric epilepsy candidate, by exercising an option — adding a differentiated CNS asset without full in-house discovery costs. The acquisition of UK-based Diurnal expanded the company's European endocrinology footprint to complement Crenessity's US launch. A historical collaboration with Eli Lilly provided Neurocrine up to $74 million in development funding, reflecting the company's longstanding use of partnerships to manage capital deployment across its broad therapeutic scope.

FAQ Section

With INGREZZA generating $2.51 billion in 2025 sales and Crenessity delivering $301.2 million in its first full year, Neurocrine has a rare combination of a cash-generative flagship and a newly launched rare-disease franchise. INGREZZA's exclusivity runway extends at least to March 2038 under the ANDA settlement terms, providing a durable revenue base to fund the late-stage pipeline. The real strategic question is whether osavampator in depression can seed a third commercial franchise before the INGREZZA patent cliff arrives.

Classic CAH results from impaired cortisol synthesis, which triggers ACTH overproduction and downstream androgen excess. Conventional management relies on supraphysiologic glucocorticoid doses to suppress ACTH — effective at controlling androgens but toxic over a lifetime, causing weight gain, insulin resistance, growth impairment, and adrenal suppression. By antagonizing the CRF1 receptor, crinecerfont suppresses ACTH at the pituitary level, allowing glucocorticoid doses to be lowered toward physiologic ranges while maintaining androgen control — a fundamentally different and less metabolically damaging approach.

Durability data are critical in CAH because the disease requires lifelong management and the metabolic consequences of high glucocorticoid exposure compound over time in children. The two-year CAHtalyst Pediatric open-label extension showed mean GC doses falling from 16.4 to 13.2 mg/m²/day, 60% of patients with obesity at baseline achieving meaningful BMI improvements, 61% of those with baseline insulin resistance becoming insulin-free, and slowed bone age progression with improved predicted adult height. These are outcomes that define quality of life and long-term health in a pediatric chronic disease — and they make the case for early, sustained treatment.

Osavampator (NBI-1065845) is Neurocrine's Phase III CNS candidate in major depressive disorder, with top-line data expected in late 2026. Depression represents a vastly larger addressable market than either tardive dyskinesia or CAH, and a successful readout would validate Neurocrine's CNS platform beyond movement disorders. The program also covers schizophrenia, meaning a positive signal in depression could unlock two significant commercial opportunities simultaneously.

Neurocrine operates at the intersection of neurology, psychiatry, and endocrinology — three fields where the company believes target biology is tractable but treatment options remain inadequate. The commercial portfolio anchors in movement disorders (INGREZZA for tardive dyskinesia and Huntington's chorea) and rare endocrinology (Crenessity for classic CAH). The pipeline extends into major depression, schizophrenia, epilepsy (NBI-921355), and a Phase II tardive dyskinesia program (NBI-1065890), building defensible depth across all three therapeutic pillars.

Neurocrine is firmly in the commercial stage, with two FDA-approved, revenue-generating products and a late-stage pipeline approaching key inflection points. The near-term lifecycle is defined by scaling Crenessity's launch, sustaining INGREZZA growth against a competitor in the VMAT2 inhibitor space, and awaiting the Phase III osavampator readout in late 2026. Beyond that, NBI-921355 in epilepsy and NBI-1065890 in tardive dyskinesia represent earlier-stage optionality within established franchises.

Key watchpoints include:

Phase III osavampator top-line data expected late 2026 — binary event for the pipeline's CNS ambitions and a potential third commercial franchise
Continued Crenessity enrollment growth and prescription trajectory as the rare-disease launch matures
INGREZZA competitive dynamics versus AUSTEDO XR in the VMAT2 inhibitor market, where head-to-head target occupancy data favor Neurocrine but commercial execution matters equally
Generic INGREZZA entry terms (earliest March 2038 for most settling parties) — a long runway, but investors will increasingly discount the tail
Execution risk under a relatively new CEO and CMO as the company navigates its most pipeline-active period in years

Want to Update your Company's Profile?